Skyrizi

What is Skyrizi?

Skyrizi (risankizumab-rzaa) is a prescription medication for adults with moderate to severe Crohn’s disease. With Skyrizi: symptom relief, lasting remission at 1 year, and endoscopic improvement may be achievable.

How does Skyrizi Work?

Skyrizi is the first treatment for Crohn’s disease that works differently by specifically targeting the interleukin-23 (IL-23) protein, which is one of the key proteins responsible for inflammation in the body. By targeting IL-23, Skyrizi can help reduce the excess inflammation that may contribute to Crohn’s symptoms.

Adults with Crohn’s disease will receive their starter doses of Skyrizi by intravenous (IV) infusion over at least one hour at Week 0, Week 4, and Week 8 of treatment in a doctor's office. Further treatment is subcutaneous.